Daxor Corporation CEO said in part: “Our Net Asset Value NAV has increased to $6.75 per share, up from $6.33 per share at this time last year. More impressively, our unaudited revenue for the first half of 2024 has more than doubled compared to the same period in 2023, marking a year-on-year growth exceeding 100%. This substantial increase is attributed to rising sales from existing customers and the addition of fourteen new accounts so far this year, already surpassing the twelve new accounts added in 2023. Our Operating Division is making significant strides towards profitability. The net cash investment for the first half of 2024 was $1.297 million, a substantial reduction from $2.445 million in the first half of 2023. This improvement comes despite increased spending on sales expansion and R&D for our upcoming product launch, demonstrating our commitment to efficient capital allocation. Looking ahead, we remain confident in achieving operational positive cash flow by the end of Q4 2024, driven by our commercial growth and newly awarded government contracts.Expansion and Recognition: Our BVA technology continues to gain traction nationwide. Notable achievements include:Launch of our BVA program at the largest integrated network in the Mid-South…”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXR:
- Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network
- Daxor announces launch of BVA program at mid-south largest integrated network
- Daxor awarded $1.9M contract by the U.S. Air Force
- Daxor expands blood volume analysis in three new facilities